The fifth batch of nationally selected drugs started to be listed on the Internet, where should the medical representatives go?

With the gradual advancement of the fifth batch of national procurement and pharmaceutical companies have entered the market one after another, where should the medical representatives go

01 The fifth batch of national procurement, issued by 7 provinces and cities

On August 11, the Public Resources Exchange Administration of Ningxia Hui Autonomous Region issued the "Notice on Carrying out the Fifth Batch of National Organized Drug Centralized Procurement of Selected Drugs (Ningxia) Qualification Application"

The notice shows that under the premise of ensuring the supply of selected drugs in the "National Drug Centralized Procurement (Ningxia) Selection Results Table", selected companies that choose to supply Ningxia can voluntarily apply for the corresponding "National Drug Centralized Procurement List of Drugs Supply after Selection".

With the continuous advancement of the fifth batch of national procurement, not only Ningxia, but other provinces/cities are also accelerating the process

Anhui

On July 28, the Anhui Provincial Pharmaceutical Centralized Procurement Service Center issued the "Notice on Declaring the Information of Selected Products Related to the Fifth Batch of National Organizations for Centralized Procurement of Drugs

The notice shows that the "National Drug Centralized Procurement Selection Result Form (GY-YD2021-2)" and "National Drug Centralized Procurement Selection List (GY-YD2021-2)" of the varieties supplied to Anhui have not yet been declared in Anhui Province According to the drug product regulations, companies need to submit relevant product information in the drug centralized bidding system

Jiangxi

On July 20, the Jiangxi Provincial Medical Security Bureau issued the "Notice on Launching the Fifth Batch of National-Organized Drug Centralized Procurement of Drugs Related to Online Procurement

The notice clarified the online filling information and the determination of the distribution relationship for the selected drugs in Jiangxi area, and the online filling information and price declaration for the non-selected drugs in Jiangxi area

Xinjiang

On July 15, the drug procurement management platform of Xinjiang medical institutions issued the "Notice on Doing a Good Job in the Preparation of the Fifth Batch of National Organizations in Our Region for Centralized Procurement of Drugs

The notice shows that the pre-declared drug purchase quantity (unmultiplied purchase ratio) in each coordinating area will be provided to the company (for reference only) so that the manufacturer can select and stock the distribution company in advance.

In response to 211 product regulations, Xinjiang declared the number of drug purchases in 14 cities/districts/autonomous prefectures in Xinjiang

Guizhou

On July 13, the Guizhou Provincial Public Resources Trading Center issued the "Notice on Carrying out the Fifth Batch of National Drug Centralized Procurement of Selected Species Qualification Materials in Guizhou Province

The notice shows that the fifth batch of national drug centralized procurement application for selected varieties in Guizhou Province will be carried out, and the application time will be from July 14, 2021 to July 20, 2021

Shanghai

On July 12, Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on Launching the Fifth Batch of National Drug Centralized Procurement of Selected Drugs in Shanghai"

According to the notice, starting from July 13, 2021, companies will log in to the "Shanghai Pharmaceutical Purchasing Service and Supervision Information System" and enter the "Drug Declaration" sub-column, and select "Selected Varieties in the National Centralized Procurement of Drugs" in the type of listing to report to the Shanghai area.

Guangdong

On July 8, the Guangdong Provincial Drug Exchange Center issued the "Notice of the Guangdong Provincial Drug Exchange Center on the Implementation of the Fifth Batch of National Organized Drug Centralized Procurement of Selected Drugs and Maintenance of Distribution Relationships

The notice shows that the fifth batch of national centralized procurement of selected drugs and the maintenance of distribution relations will be carried out on the third-party drug electronic trading platform of Guangdong Province
.
The application time for the selected drugs is from July 8, 2021 to July 23, 2021, and relevant selected companies are required to register for the selected drugs through the provincial platform within the specified time
.

The distribution relationship maintenance period is from July 8, 2021 to July 31, 2021, and stipulates that the distribution relationship can be designated after the registration of the selected drugs takes effect.
Complete the designated work of the distribution relationship within the specified time
.
The distribution and supply of medical institutions at or above the county level shall be designated by the selected enterprise with the prefecture and city as the unit; the distribution and supply of the primary medical and health institutions shall be designated by the selected enterprise with the county (city, district) as the unit.
There shall be no more than 5 counties (cities, districts)
.

02 Medical representatives, where to go

The fifth batch of national sourcing is the largest number of national sourcing in the past, and the purchase amount exceeds 55 billion yuan
.
There were 61 selected varieties, involving 251 products from 148 companies, with an average decrease of 56%
.

According to the data released by the National Medical Insurance Administration and static calculations based on the agreed procurement volume, the first four batches of centralized procurement involved 157 varieties, saving 67.
1 billion yuan
.

The normalization of volume purchases has become the consensus of the industry, the price of medicines has fallen, and the market structure has changed
.
For medical representatives, these data mean that the market scale has shrunk dramatically, drug prices continue to fall, and the industry reshuffle is about to come
.

It is reported that the competition among the fifth batch of state-owned pharmaceutical companies is even more intense than in the past
.
Insight database statistics show that there are more than 6 competing companies in 19 varieties
.
In terms of large varieties, 26 drugs have sales of more than 1 billion yuan
.
Among them, budesonide inhalation leads with nearly 6 billion yuan, followed by ceftazidime injection with over 5 billion yuan
.

According to Cyberlan’s previous analysis, many pharmaceutical companies have emerged from the five batches of national sourcing, and many large varieties have been selected.
Qilu Pharmaceutical, China Biopharmaceuticals, Yangzijiang and many other well-known pharmaceutical companies have multiple large varieties
.

Most of these pharmaceutical companies are leading domestic pharmaceutical companies with an annual R&D investment of more than 2 billion yuan.
Among them, many pharmaceutical companies have successfully passed the consistency evaluation for generic drugs
.

Judging from the current decline in medicines, some medicines have dropped by more than 90%
.
Although the wave of drug price cuts has arrived, many pharmaceutical companies have already taken corresponding measures after the previous rounds of national procurement
.

At the same time, with the normalization of national procurement and mass procurement, it is believed that more pharmaceutical companies will invest funds in research and development to develop more innovative drugs to avoid fierce competition
.
For medical representatives, new opportunities have also come
.